CardioVascular and Interventional Radiology

, Volume 33, Issue 3, pp 552–559 | Cite as

Bland Embolization in Patients with Unresectable Hepatocellular Carcinoma Using Precise, Tightly Size-Calibrated, Anti-Inflammatory Microparticles: First Clinical Experience and One-Year Follow-Up

  • Guido BonomoEmail author
  • Vittorio Pedicini
  • Lorenzo Monfardini
  • Paolo Della Vigna
  • Dario Poretti
  • Gianluigi Orgera
  • Franco Orsi
Clinical Investigation


The purpose of this study is to report on the feasibility, local response, and 1-year clinical outcome of bland transarterial embolization (TAE) with 40- and 100-μm Embozene microspheres in patients affected by unresectable hepatocellular carcinoma (HCC). Up to January 2009, 53 patients underwent superselective TAE for a total of 74 lesions. Diagnosis of HCC was based on multidetector computed tomography (MDCT), α-fetoprotein, and biopsy. MDCT was performed 24 after treatment and repeated at 1 month, 3 months, and then every 6 months. Local efficacy was defined according to RECIST criteria. Technical success was always achieved. Local results at 1-month, 3- to 6-month, and 6- to 12-month follow-up were 62%, 37%, and 16%, respectively, for stable disease and 35%, 56%, and 51%, respectively, for partial response. Complete response (no evidence of lesion) has been observed only at late follow-up (three lesions; 7%). To date, 20 of 53 patients have had at least 1 year of follow-up, with an overall survival rate of 96%. Hepatic progressive disease (i.e., new nodules) was observed in 14 of 20 patients due to underlying liver disease. Minor complications were observed in four patients. A major complication occurred in one patient, who died unexpectedly 24 h after TAE due to pulmonary embolism of necrotic pathologic tissue and passage of particles through a disrupted hepatic vein. Local results as well as 1-year clinical outcome after TAE with Embozene microspheres are veryly encouraging, however, further studies, a larger patient population, and a longer follow-up are mandatory to assess the real clinical impact.


Hepatocellular carcinoma Embolization Chemoembolization Microparticles 


  1. 1.
    Alba E, Valls C, Dominguez J et al (2008) Trancatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR 190(5):1341–1348CrossRefPubMedGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J et al (2002) Global cancer statistics 2002. CA Cancer J Clin 55(2):74–108CrossRefGoogle Scholar
  3. 3.
    El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340(10):745–750CrossRefPubMedGoogle Scholar
  4. 4.
    El-Serag HB, Davial JA, Petersen NJ et al (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139(10):817–823PubMedGoogle Scholar
  5. 5.
    Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739CrossRefPubMedGoogle Scholar
  6. 6.
    Schwartz M, Roayaie S, Konstadoulakis M (2007) Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4(7):424–432CrossRefPubMedGoogle Scholar
  7. 7.
    Clark HP, Carson WF, Kavanagh PV et al (2005) Staging and current treatment of hepatocellular carcinoma. Radiographics 25(Suppl 1):S3–S23CrossRefPubMedGoogle Scholar
  8. 8.
    Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362(9399):1907–1917 [review]Google Scholar
  9. 9.
    Lubienski A (2005) Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation 80(Suppl 1):S113–S119CrossRefPubMedGoogle Scholar
  10. 10.
    Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):179–188CrossRefGoogle Scholar
  11. 11.
    Camma C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled. Radiology 224(1):47–54CrossRefPubMedGoogle Scholar
  12. 12.
    Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442CrossRefPubMedGoogle Scholar
  13. 13.
    Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference, for the EASL Panel of Experts on HCC. J Hepatol 35(3):421–430Google Scholar
  14. 14.
    Arakawa A, Nishiharu T, Matsukawa T et al (1996) Detection of hepatocellular carcinoma by intraarterially enhanced ultrasonography with CO2 microbubbles. Comparison with DSA, dynamic CT, and Lipiodol CT. Acta Radiol 37(3 Pt 1):250–254CrossRefPubMedGoogle Scholar
  15. 15.
    Merlino R, Orsi F, Bezzi M et al (1994) Carbon dioxide as an intra-arterial contrast agent in echography: a technique for its preparation and the preliminary results in assessing hepatocarcinoma vascularisation. Radiol Med 88(3):259–265PubMedGoogle Scholar
  16. 16.
    Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278CrossRefPubMedGoogle Scholar
  17. 17.
    Chen JH, Chai JW, Huang CL et al (1999) Proximal arterioportal shunting associated with hepatocellular carcinoma: features revealed by dynamic helical CT. AJR 172(2):403–407PubMedGoogle Scholar
  18. 18.
    Hung JC, Redfern MG, Mahoney DW et al (2000) Evaluation of macroaggregated albumin particle sizes for use in pulmonary shunt patient studies. J Am Pharm Assoc 40(1):46–51Google Scholar
  19. 19.
    Brown DB, Cardella JF, Sacks D et al (2006) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 17:225–232CrossRefPubMedGoogle Scholar
  20. 20.
    Llovet JM, Brù C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–339CrossRefPubMedGoogle Scholar
  21. 21.
    Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of trasarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164–1171CrossRefPubMedGoogle Scholar
  22. 22.
    Miraglia R, Pietrosi G, Maruzzelli L et al (2007) Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol 13(21):2953–2955Google Scholar
  23. 23.
    Lin DY, Lee TY, Liaw YF et al (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 94(2):453–456PubMedGoogle Scholar
  24. 24.
    Pelletier G, Roche A, Ink O et al (1990) A randomized trial of hepatic arterial chemoembolization in patient with unresectable hepatocellular carcinoma. J Hepatol 11(2):181–184CrossRefPubMedGoogle Scholar
  25. 25.
    Madden MV, Krige JE, Bailey S et al (1993) Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 34(11):1598–1600CrossRefPubMedGoogle Scholar
  26. 26.
    Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced HCC: results of randomized controlled trial in a single institution. Hepatology 27(6):1578–1583CrossRefPubMedGoogle Scholar
  27. 27.
    Pelletier G, Ducreux M, Gay F et al (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 29(1):129–134CrossRefPubMedGoogle Scholar
  28. 28.
    Grosso M, Vignali C, Quaretti P et al (2008) Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. CardioVasc Interv Radiol 31(6):1141–1149CrossRefGoogle Scholar
  29. 29.
    Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. CardioVasc Interv Radiol 30(1):6–25CrossRefGoogle Scholar
  30. 30.
    Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRefPubMedGoogle Scholar
  31. 31.
    Ramsey DE, Kernagis LY, Soulen MC et al (2002) Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 13(9; Pt 2):211–221CrossRefGoogle Scholar
  32. 32.
    Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276(46):43407–43412CrossRefPubMedGoogle Scholar
  33. 33.
    Tajima T, Honda H, Taguchi K et al (2002) Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR 178(4):885–897PubMedGoogle Scholar
  34. 34.
    Lee KH, Liapi E, Vossen JA et al (2008) Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implicationfor therapy. J Vasc Interv Radiol 19:1490–1496CrossRefPubMedGoogle Scholar
  35. 35.
    Jones JA, Chang DT, Meyerson H et al (2007) Proteomic analysis and quantification of cytokines and chemokines from biomaterial surface-adherent macrophages and foreign body giant cells. J Biomed Mater Res A 83:585–596PubMedGoogle Scholar
  36. 36.
    Kobayashi N, Ishii M, Ueno Y et al (1999) Co-expression of Bel-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 19(1):25–31CrossRefPubMedGoogle Scholar
  37. 37.
    Liou TC, Shih SC, Kao CR et al (1995) Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol 23(5):563–568CrossRefPubMedGoogle Scholar
  38. 38.
    Sergio A, Cristofori C, Cardin R et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103(4):914–921CrossRefPubMedGoogle Scholar
  39. 39.
    Mamori S, Asakura T, Ohkawa K et al (2007) Survivin expression in early hepatocellular carcinoma and post-treatment with anticancer drug under hypoxic culture condition. World J Gastroenterol 13(40):5306–5311PubMedGoogle Scholar
  40. 40.
    Laurent A, Wassef M, Chapot R et al (2004) Location of vessel occlusion of calibrated tris-acryl gelatin microspheres for tumor and arteriovenous malformation embolization. J Vasc Interv Radiol 15:491–496PubMedGoogle Scholar
  41. 41.
    Dion JE, Rankin RN, Vinuela F et al (1986) Dextran microsphere embolization: experimental and clinical experience with radiologic-pathologic correlation. Radiology 160:717–721PubMedGoogle Scholar
  42. 42.
    Pillaj KM, McKeever PE, Knutsen CA et al (1991) Microscopic analysis of arterial microsphere distribution in rabbit liver and hepatic VX2 tumor. Sel Cancer Ther 7(2):39–48Google Scholar
  43. 43.
    Yamamoto A, Imai S, Kobatake M et al (2006) Evaluation of tris-acryl gelatine microsphere embolization with monochromatic X-rays: comparison with polyvinyl alcohol particles. J Vasc Interv Radiol 17:1797–1802CrossRefPubMedGoogle Scholar
  44. 44.
    Lee KH, Liapi E, Vossen JA et al (2008) Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR Imaging and implication for therapy. J Vasc Interv Radiol 19(10):1490–1496CrossRefPubMedGoogle Scholar
  45. 45.
    Amseur NB, Zajko AB, Carr BI (2008) Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles. Dig Dis Sci 53(5):1400–1404CrossRefGoogle Scholar
  46. 46.
    Maluccio MA, Covey AM, Porat LB et al (2008) Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 19(6):862–869CrossRefPubMedGoogle Scholar
  47. 47.
    Stampfl U, Stampfl S, Bellemann N et al (2009) Experimental liver embolization with four different spherical embolic materials: impact on inflammatory tissue and foreign body reaction. CardioVasc Interv Radiol 32(2):303–312CrossRefGoogle Scholar
  48. 48.
    Bilbao JI, de Martino A, de Luis E et al (2009) Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. CardioVasc Interv Radiol 32(4):727–736CrossRefGoogle Scholar
  49. 49.
    Brown KT (2004) Fatal pulmonary complications after arterial embolization with 40–120 μm tris-acryl gelatine microspheres. J Vasc Interv Radiol 15(2; Pt 1):197–200PubMedGoogle Scholar
  50. 50.
    Noguera PJJ, Martinez-Cuesta A, Sangro B et al (2008) Embolismo pulmonary fatal tras la embolizaciòn con microsferas de un hepatocarcinoma. Radiologia 50:248–250CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2009

Authors and Affiliations

  • Guido Bonomo
    • 1
    Email author
  • Vittorio Pedicini
    • 2
  • Lorenzo Monfardini
    • 1
  • Paolo Della Vigna
    • 1
  • Dario Poretti
    • 2
  • Gianluigi Orgera
    • 1
  • Franco Orsi
    • 1
  1. 1.Unit of Interventional RadiologyEuropean Institute of OncologyMilanItaly
  2. 2.RadiologyIstituto Clinico HumanitasRozzano, MilanItaly

Personalised recommendations